Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma.

Curiox Biosystems announces its collaboration with Dr. Marco Ruella, an assistant professor of medicine at the Perelman School of Medicine, to support efforts in the development of next-generation cancer cell therapies.

Orano Med SAS, and Orbit Discovery Ltd, announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development of novel radiopharmaceuticals.

AMSBIO has supplied a custom monoclonal antibody (mAB) to researchers at the TU Dortmund** in Germany to unravel the role of EDI3 in breast cancer development.

Introducing The Alpha Portal (TAP) by Alpha Laboratories.

Cytiva has launched the NanoAssemblr commercial formulation system, purpose-built for clinical and commercial manufacturing of lipid nanoparticle medicines.

A landmark study demonstrates that precision oncology medicines could deliver a superior return on Investment for Pharma R&D vs their one size fits all counterparts.

Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc. for the use of their investigational CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam) technology.

Thermo Fisher Scientific has announced the launch of the first commercially available culture medium specifically developed for the expansion of patient-derived cancer organoids, from multiple cancer indications.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility.